Union Therapeutics begins phase IIb trial of eczema tablet

The pharmaceutical firm is aiming to find the proper dose strength of tablet orismilast before heading into phase III.

Denmark-based Union Therapeutics has yet to bring a product to market, but has several late-stage trials planned for lead-candidate orismilast | Photo: Union Therapeutics / PR

Union Therapeutics has enrolled its first patient in a phase IIb trial and aims to find a total of 210 participants, the firm reports in a press release.

In the Adesos study, patients with atopic eczema will be administered tablet candidate orismilast. Union Therapeutics is hoping to find the proper regimen for further phase III testing, and the firm will therefore investigate dose strengths of 20, 30, and 40 mg.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs